Serum Life Science Europe GmbH
Quick facts
Phase 3 pipeline
- VPM1002 · Immunology / Infectious Disease
VPM1002 is a live attenuated recombinant tuberculosis vaccine that enhances immune response by expressing listeriolysin O to improve intracellular antigen presentation.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Serum Life Science Europe GmbH portfolio CI brief
- Serum Life Science Europe GmbH pipeline updates RSS
Frequently asked questions about Serum Life Science Europe GmbH
What is Serum Life Science Europe GmbH's pipeline?
Serum Life Science Europe GmbH has 1 drugs in Phase 3, 1 in Phase 2, 2 in Phase 1. Late-stage candidates include VPM1002.
Related
- Sector hub: All tracked pharma companies